Skip to main content
Loading

AI Productivity Enhancements for Developing Assets

October 16, 2024
Venetian Room
As the newest iterations of commercial and open-source molecular modeling tools and large-language models lower the barriers for implementing AI applications at biotechs, the challenge for management teams shifts to separating hype from substance among investment options within the pre-clinical and clinical development planning. This session will prioritize the AI-related productivity enhancements available now for biotechs already developing assets to help gather biochemical evidence more efficiently and advance to clinical results sooner.
Moderator
Ruchita Sinha, General Partner - AV8 Ventures
Speakers
Matt Foehr, President and Chief Executive Officer - OmniAb
Alan Joslyn - PhD, Chief Executive Officer - Inimmune Inc.
Michelle Longmire - MD, CEO & Co-founder - Medable
Greg Notte - PhD, Executive Director, Medicinal Chemistry - Gilead Sciences
Renee Yao, Ecosystem Business Development, Healthcare Life Sciences - NVIDIA

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS